Skip to main content

Table 2 The difference between female and male subjects with (IS) or without (non-IS) immunosuppression (non-IS) in respect to the body site of melanoma

From: High regional mortality due to malignant melanoma in Eastern Finland may be explained by the increase in aggressive melanoma types

 

Female (158)

Male (179)

p-value

Non-IS Female (97)

Non-IS Male (98)

p-value

IS Female (61)

IS Male (81)

p-value

Total (337)

HN

43.0%

29.1%

0.007

47.4%

27.6%

0.004

36.1%

30.9%

0.514

35.6%

Trunk

19.0%

46.4%

< 0.001

16.5%

42.9%

< 0.001

23.0%

50.6%

0.001

33.5%

UL

12.0%

12.3%

0.941

14.4%

16.3%

0.714

8.2%

7.4%

0.862

12.2%

LL

14.6%

3.4%

< 0.001

13.4%

2.0%

0.003

16.4%

4.9%

0.023

8.6%

Foot/sole

7.0%

5.6%

0.602

6.2%

6.1%

0.985

8.2%

4.9%

0.430

6.2%

Palm

3.2%

1.7%

0.370

2.1%

2.0%

0.992

4.9%

1.2%

0.189

2.4%

GPA

1.3%

0.6%

0.490

0.0%

1.0%

0.319

3.3%

0.0%

0.101

0.9%

N.S.

0.0%

1.1%

N.D.

0.0%

2.0%

N.D.

0.0%

0.0%

N.D.

0.6%

  1. HN = head & neck; UL = upper limb; LL = lower limb; GPA = genitalia/perianal area; N.S. = not specified; N.D. = no data